Leaders in Supply & Demand Side Intelligence

Forgot your login?

Enter the e-mail address you used when you registered an account with IIR Energy.

A message will be sent to the E-Mail Address found in our records containing the associated username(s) as well as instructions for a password reset.


India's Bharat Serum and Vaccines to Repurpose Sepsis Drug for COVID-19, an Industrial Info Market Brief

Free News Article

Indian vaccine-maker Bharat Serums and Vaccines Limited (BSVL) said it has received approval from the Drug Controller General of India (DCGI) to conduct the Phase III clinical trial of Sepsis drug Ulinastatin on COVID-19 patients showing mild-to-moderate acute respiratory distress symptoms.

Ulinastatin is used in India, China and Japan in the treatment of severe sepsis and other critical clinical conditions such as acute pancreatitis. Clinical trials to evaluate efficacy of the drug are likely to commence soon in six hospitals across India, enrolling 120 patients. Results are expected to be available by December 2020.

Details on this Article:
Industry Segment: Market Brief
Word Count: 96 Words
Listen to Today's News News Audio Library Sync News Podcasts

Login or Register now for instant access!
Related Articles


This article is free for all Registered Members.

Register Now! All Fields are Required...

Pricing Help?

Upgrade your Premium News Subscription to include all archived articles for only $160. Contact Member Services: 800-762-3361

All Members Receive the Following Free Resources:

  • North American Project & Gap Spending
  • North American Plant Analysis by Industry & Market Region
  • Market Maps & Stats - Capital & Maintenance Activity
  • Current & Historic Economic Indicators
  • 30/60/90 Day Weather Forecast